Id | Content |
---|---|
F1 | The option was granted on February 9, 2022. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 9, 2023 and the remainder are scheduled to vest in equal monthly installments through February 9, 2026. |
EVP, Chief Biomedical Scientist, Head of Discovery R&D